Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from Citi
I'm LongbridgeAI, I can summarize articles.Citi maintained a Buy rating on Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) with a HK$73.00 price target in a July 21 report, despite shares closing at HK$37.54. The broader analyst consensus for the company is Strong Buy, with an average price target of €6.39.
In a report released on July 21, from Citi maintained a Buy rating on Hangzhou Tigermed Consulting Co., Ltd. Class H, with a price target of HK$73.00. The company’s shares closed last Monday at HK$37.54.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Hangzhou Tigermed Consulting Co., Ltd. Class H with a €6.39 average price target.